Studies suggest that drugs like Ozempic (which contain GLP-1 agonists) may reduce cravings for alcohol and other addictive substances by acting on a specific brain region: the lateral septum. This area is rich in GLP-1 receptors and appears to act as a crucial control point: it integrates information about rewards (connecting memories and surroundings with rewarding experiences) and communicates with dopamine-producing regions that drive reward-seeking behavior. Research indicates that activating GLP-1 receptors in the lateral septum dampens the signaling associated with reward-seeking, potentially reducing the salience of cravings and the motivation to pursue rewards. If confirmed, this could open new avenues for treating both addiction and obesity.
About the Author
